Eiger BioPharmaceuticals Stock Price

-0.84 (-7.08%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Eiger BioPharmaceuticals Inc EIGR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.84 -7.08% 11.02 18:42:18
Open Price Low Price High Price Close Price Prev Close
11.84 10.98 12.071 11.02 11.86
Bid Price Ask Price Spread News
10.79 11.75 0.96 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,453 332,525 $ 11.48 $ 3,816,528 675,921 4.55 - 15.12
Last Trade Time Type Quantity Stock Price Currency
18:03:30 15 $ 11.02 USD

Eiger BioPharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 358.50M 32.53M 31.97M $ - $ - -3.09 -4.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 1.10%

more financials information »

Eiger BioPharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EIGR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.6812.169910.9811.59370,555-0.66-5.65%
1 Month10.0312.759.4111.29560,1600.999.87%
3 Months10.0012.758.5810.21578,0091.0210.2%
6 Months9.7712.757.5710.19533,0221.2512.79%
1 Year14.5915.124.5510.08442,219-3.57-24.47%
3 Years9.6018.004.5510.65248,6651.4214.79%
5 Years17.4023.104.5510.72170,786-6.38-36.67%

Eiger BioPharmaceuticals Description

Eiger BioPharmaceuticals Inc is a late-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Your Recent History
Eiger BioP..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.